Nurse Practitioner, Family · New York, NY
NPI
1902498041
Since 2021
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
5 E 98th St
New York, NY, 10029
Phone (212) 241-6854
Groups this clinician bills Medicare through
Medicare paid, 2024
$6,004
82 services
Medicare patients, 2024
30
Average age 62
Drug cost, 2024
$3.3M
1,601 prescriptions
Company payments, 2025
$139
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anastasia M Lyras was code 99215 (office e&m - established), 33 times for 23 patients. In total Anastasia M Lyras billed 82 services in 9 codes, and Medicare paid $6,004.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 33 | 23 | $123.99 | $4,092 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 25 | 19 | $12.15 | $304 |
By year: 2022 $5,402 for 46 services; 2023 $3,187 for 37 services; 2024 $6,004 for 82 services.
Medicare prescription drug claims, 2024
In 2024, the drug Anastasia M Lyras prescribed most often to Medicare patients was Baclofen, with 157 prescriptions and refills. In total Anastasia M Lyras wrote 1,601 Medicare prescriptions that cost $3.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Baclofen Generic | 157 | 264 | 51 | $4,205 |
| Gabapentin Generic | 128 | 180 | 36 | $2,215 |
| Dimethyl Fumarate Generic | 106 | 140 | 21 | $84K |
| Dalfampridine Er Dalfampridine | 94 | 155 | 25 | $57K |
| Copaxone Glatiramer Acetate | 92 | 116 | 15 | $666K |
| Teriflunomide Generic | 55 | 73 | 11 | $115K |
| Glatiramer Acetate Generic | 47 | 60 | Under 11 | $156K |
| Modafinil Generic | 47 | 55 | 11 | $3,306 |
| Duloxetine Hcl Generic | 44 | 62 | Under 11 | $831 |
| Ampyra Dalfampridine | 43 | 43 | Under 11 | $171K |
| Fingolimod Fingolimod Hcl | 42 | 60 | Under 11 | $123K |
| Tizanidine Hcl Generic | 41 | 69 | 14 | $296 |
| Tecfidera Dimethyl Fumarate | 39 | 39 | Under 11 | $342K |
| Ibuprofen Generic | 31 | 31 | Under 11 | $67.33 |
| Kesimpta Pen Ofatumumab | 30 | 30 | Under 11 | $247K |
Brand drugs: 339 claims; generic drugs: 1,262 claims; opioid claims: 17.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anastasia M Lyras $139 ($139 in general payments such as food, travel and fees) from 2 companies. The largest payer was Biogen, Inc. with $89.43.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.